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Abstract
The purpose of this research and systematic literature review is to determine
which pharmacotherapeutic agent, methadone or buprenorphine, leads to
better outcomes in cases of pregnant mothers with opioid use disorder
(OUD). Outcomes considered are maternal compliance, neonatal abstinence
syndrome severity, and neonatal length of hospital stay. In the review,
PubMed, Clinical Key, Cochrane Database of Systematic Reviews, and
DynaMed Plus were searched. Key terms searched were “methadone,
buprenorphine, pregnancy”, “opioids, pregnancy”, “neonatal abstinence
syndrome” and “medication assisted treatment, pregnancy”. Several studies
were excluded, as their study population was not specified to have diagnosed
OUD in pregnancy. The drawbacks to many of the studies is the
inconsistencies in study conditions, and very small sample sizes. Much of
the research presented shows evidence for the use of buprenorphine in the
treatment of OUD in pregnancy. Buprenorphine seems to be a better
medication assisted treatment (MAT) for the neonate in terms of reduced
neonatal abstinence syndrome (NAS) and reduced length of hospital stay
postpartum, while methadone still performs better for adherence for the
mother. More research still needs to be done in order to demonstrate
buprenorphine’s superior efficacy compared to methadone use in pregnant
patients with OUD.
Keywords: MAT, methadone, buprenorphine, pregnancy, OUD, opioid,
addiction, NAS, neonate

Introduction
Opioid addiction in the United States has become a major public
health crisis. The Centers for Disease Control and Prevention (CDC)
estimates that 134 people die from opiate overdose each day.
Neonates who are heavily exposed to opiates in utero often
experience withdrawal upon parturition, a condition called neonatal
abstinence syndrome (NAS). NAS increased by 500% in the US
between 2000 and 2012. Treatment protocol supports the use of MAT
to prevent NAS. Currently, methadone is administered to prevent
pregnant women from abusing opiate substances, namely heroin or
prescription opiates. However, a growing body of evidence supports
other MAT drugs, most notably buprenorphine, for use in pregnant
patients.

Note. Adapted from “Children's Services Practice Notes” (2018)
North Carolina Child Welfare Social Workers, 23:2.
Retrieved from http://www.practicenotes.org/v23n2/MAT.htm

Statement of the Problem
Methadone is the current standard of care for the use of MAT in
pregnant women with OUD. Studies are needed to show the safety
and efficacy of other treatment options such as buprenorphine for
this patient population.

Research Questions

Discussion

In pregnant patients with OUD, how effective is methadone
compared to buprenorphine in the reduction of NAS?

Although buprenorphine is not the standard of care for pregnant
women with OUD, it should be considered as an alternative to
methadone maintenance therapy. NAS is reduced with
buprenorphine compared to methadone treatment, though more
women sustain MAT with methadone. Because NAS is less
severe with buprenorphine MAT compared to methadone MAT,
length of stay (LOS) is less with buprenorphine exposed
neonates and thus is a more effective way to spend the very
limited healthcare dollars that exist for these patients. In addition,
MAT drug choice should be individual. Finally, if one MAT drug
is failed, another should be initiated.
Methadone Versus Buprenorphine

In pregnant patients with OUD, how effective is methadone
compared to buprenorphine in the reduction in length of hospital
stay for neonates?
In pregnant patients with OUD, how effective is methadone
compared to buprenorphine in retention on MAT and prevention
of relapse?

Literature Review
Maintenance treatment provides a steady concentration of opiate
in the pregnant woman’s blood and so prevents the adverse effects
on the fetus of repeated withdrawals (Minozzi et al., 2013). In
conjunction with psychosocial and cognitive behavioral therapy,
MAT is endorsed over medically assisted withdrawal or
abstinence for pregnant women with OUD by the Substance
Abuse and Mental Health Services Administration and the
American College of Obstetricians and Gynecologists
Committee (Tran, Griffin, Stone, Vest, & Todd, 2017).
• Fowler et al., (2013) found that buprenorphine led to better
outcomes for neonates but had dropout rates of 56.4%
compared to methadone. Also, buprenorphine led to a cost
savings of over $12.4 million healthcare dollars.
• Jansson et al., (2017) found that of mothers treated with
buprenorphine, had a high dropout rate, and total length of
hospitalization of neonates was 14.7 days on average.
• A Cochrane review found that mothers on methadone therapy
are less likely to drop out of the study (RR 0.64, 95% CI 0.41 to
1.01, n=223) compared to those on buprenorphine. There was
no significant difference in the number of newborns treated for
NAS, but evidence is considered very low (RR 1.22, 95% CI
0.89 to 1.67, three studies, n=166) (Minozzi et al., 2013).
• The MOTHER study by Jones et al., (2010) showed
discontinuation of treatment occurred in 18% of women in
methadone treatment and 33% of women in buprenorphine
treatment (p=0.02). The number of neonates requiring NAS
treatment was not significantly different between groups
(p=0.26). Neonates from the buprenorphine group needed 89%
less morphine than those exposed to methadone (p<0.0091) and
spent 43% less time in the hospital (p<0.0091).
• Pregnant women addicted to intravenous heroin were studied in
a five-year randomized prospective comparative study by
Binder and Vavřinková (2008). The degree of NAS severity was
9.2 in the buprenorphine group, 11 in the heroin group, and 17.8
in the methadone group (buprenorphine to methadone
p<0.000001, heroin to methadone p<0.00001).

Note. Adapted from “Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure” by H.E. Jones, et al., 2010. The New
England Journal of Medicine, 363;24 p 2327. Copyright © 2010 Massachusetts Medical Society
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Applicability to Clinical
Practice
North Dakota experiences opioid addiction across the state but
faces challenges for patients to get the care they need due to a lack
of specialists and a vastness of rural geography. Since stigma still
exists with MAT, providers should be given the tools to screen,
refer, and care for pregnant mothers with OUD. Withdrawal during
pregnancy should be discouraged, and personal judgements
withheld.
• Project ECHO or “Extension for Community Healthcare
Outcomes” is a hub and spoke model used to train rural providers
with resources and information through video conferencing.
Project ECHO is focused on the opioid epidemic in North Dakota
and provides video sessions weekly from experts and specialists in
academic or health care centers to primary care teams in rural parts
of the state.
• Champion Prescriber initiative expands access to MAT in North
Dakota. These providers provide MAT treatment and overdose
prevention education, collaborate with providers in project ECHO,
and provide training on the use of Naloxone.
• The First Steps to Healthy Babies service provided by Sanford in
Bemidji, MN aims to help women have safe and healthy
pregnancies and encourages sobriety with support services. They
have seen a significant increase in the number of mothers who
undergo MAT during pregnancy and are able to return home with
their infant.
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